Home / Themes / GLP-1 Long '24: GLP-1 Producers & Obesity Therapeutics

GLP-1 Long '24: GLP-1 Producers & Obesity Therapeutics (open on stockthemes)

Last updated

Theme thesis · 3/5 sections · Tickers 7 with notes · 8 pending

Loading chart…
Loading…

Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).

Bull / Bear Details

The obesity-treatment market is expanding beyond first-generation injectable GLP-1 therapies into oral formulations, multi-receptor agonists, amylin-based combi

Thesis

The obesity-treatment market is expanding beyond first-generation injectable GLP-1 therapies into oral formulations, multi-receptor agonists, amylin-based combinations and longer-acting treatments. Companies developing and commercializing differentiated obesity medicines can capture demand through superior weight loss, tolerability, convenience, metabolic benefits and broader insurance coverage.

Bull case

  • Expanded reimbursement, obesity diagnosis and treatment eligibility increase the number of patients receiving chronic pharmacological weight management, supporting prescription growth and potentially longer treatment duration.

  • Oral GLP-1 drugs, monthly injections, triple-receptor agonists and amylin combinations improve convenience or clinical outcomes, expanding treatment choices and creating opportunities for differentiated products beyond semaglutide and tirzepatide.

  • Additional indications involving cardiovascular risk, sleep apnea, kidney disease and metabolic liver disease could broaden eligible patient populations while supporting pharmaceutical pricing, reimbursement and long-term treatment adherence.

Bear case

  • Competition among established manufacturers, oral-drug developers and emerging Chinese pharmaceutical companies could accelerate net-price reductions, rebate concessions and market-share losses as therapeutic alternatives proliferate.

  • Late-stage trials may reveal disappointing weight-loss efficacy, gastrointestinal intolerance, lean-mass loss or safety concerns; manufacturing scale-up and regulatory delays could prevent promising investigational drugs from achieving commercial adoption.

  • Drug affordability constraints, restrictive insurance coverage, treatment discontinuation and patient sensitivity to out-of-pocket expenses could limit sustained prescription growth despite high obesity prevalence and strong initial treatment demand.

Overview

Hiring Trend Watchpoints

High-performing operators in this theme are aggressively expanding specialized manufacturing, regulatory, and direct commercial capabilities while restructuring legacy administrative overhead. Critical workforce watchpoints include: (1) Manufacturing & Fill-Finish Scaling: Rapid hiring of process engineers, quality control specialists, and aseptic fill-finish technicians across North America, Europe, and Asia to scale peptide synthesis and oral solid-dose tableting capacity (e.g., Lilly's Lebanon and Limerick sites; Roche's Holly Springs hub); (2) Commercial & Access Reorientation: Increased recruitment of market access negotiators, payer strategy directors, and digital health engagement teams capable of navigating Medicare Part D formulary integration, employer co-pay models, and direct-to-consumer telehealth platforms (such as LillyDirect); (3) Clinical & Medical Affairs: Continued hiring of Medical Science Liaisons (MSLs) and clinical research coordinators to support late-stage Phase 3 multi-indication trials (cardiovascular outcomes, MASH, obstructive sleep apnea, osteoarthritis); (4) Automation & AI Reallocation: Redeployment of capital away from administrative headcount toward automated clinical analytics and machine-learning molecular design (evidenced by Amgen's frontier AI lab and Novo's enterprise efficiency programs). Confirmation of theme execution is marked by rising job openings in high-volume drug manufacturing facilities and primary-care commercial launch teams. Warning signs include hiring freezes across cardiometabolic sales forces, turnover in chemistry/manufacturing controls (CMC) leadership, or regulatory team attrition causing trial submission delays.

Forum Watchlist

  • subreddit — r/Zepboundhigh

    Patient adherence, pharmacy stocking and supply availability, real-world gastrointestinal tolerability, and sentiment regarding transitioning to oral alternatives or higher maintenance doses.

  • subreddit — r/WegovyWeightLosshigh

    Real-world uptake of the oral Wegovy pill versus weekly injections, discontinuation rates due to side effects, out-of-pocket payment hurdles, and commercial insurance coverage friction.

  • subreddit — r/Semaglutidemedium

    Compounding pharmacy dynamics, long-term weight maintenance protocols, titration drop-offs, and shifts in consumer willingness to pay out-of-pocket.

  • subreddit — r/tirzepatidemedium

    Discussions on comparative efficacy against earlier GLP-1s, patient adoption of Medicare GLP-1 coverage programs, and user sentiment on emerging triple agonists like retatrutide.

  • subreddit — r/biotechmedium

    KOL analysis of clinical data readouts (retatrutide TRIUMPH trials, MariTide MARITIME studies, petrelintide combinations), trial protocol integrity, and biotech licensing deal valuations.

  • subreddit — r/loseitlow

    Broader consumer attitudes toward medicalized weight management, lifestyle versus pharmacotherapy tradeoffs, and consumer stigma reduction around obesity treatments.

Industry Publications

  • Endpoints News (endpointsnews.com) — Premier biopharma news service providing real-time insider reporting on Phase 3 clinical readouts, FDA regulatory decisions, metabolic pipeline prioritization, and executive talent moves.
  • Fierce Pharma (fiercepharma.com) — In-depth commercial and operational coverage tracking drug launch trajectories, manufacturing supply expansion, pricing concessions, and PBM formulary contracts.
  • BioSpace (biospace.com) — Specialized coverage of life sciences clinical pipelines, biopharma recruitment and workforce restructuring, and emerging cross-border licensing transactions.
  • Obesity (The Obesity Society / Wiley) (onlinelibrary.wiley.com) — The leading peer-reviewed scientific journal publishing clinical trial results on incretin pharmacology, body composition changes, lean mass preservation, and metabolic comorbidities.
  • Evaluate Pharma (evaluate.com) — Essential industry forecasting intelligence tracking consensus sales projections, competitive market share shifts between oral and injectable incretins, and patent cliff exposure.

Second Order Trends

Several key second-order trends are defining the next phase of this theme: (1) Lean Mass Preservation vs. Pure Weight Loss: Clinicians and payers are increasingly evaluating quality of weight loss rather than absolute kilograms shed, driving intense pipeline interest in amylin analogs (petrelintide), myostatin inhibitors, and balanced multi-agonists that minimize muscle wasting; (2) Incretins as Multi-Organ Systemic Platforms: The narrative is shifting from cosmetic weight loss to profound comorbidity risk reduction, with major Phase 3 programs demonstrating efficacy across obstructive sleep apnea, heart failure with preserved ejection fraction (HFpEF), metabolic dysfunction-associated steatohepatitis (MASH), chronic kidney disease, and knee osteoarthritis pain; (3) Oral Convenience Battles (Small Molecule vs. Peptide): Commercialization is dividing between non-peptide small molecules (like Foundayo/orforglipron and aleniglipron) that can be taken without food or water restrictions and oral peptides (such as the Wegovy pill) requiring morning fasting protocols, reshaping primary-care prescribing habits; (4) Direct-to-Consumer & Telehealth Infrastructure: The rise of hybrid commercial models—combining traditional wholesale pharmacy distribution with manufacturer-owned digital channels (LillyDirect) and telehealth prescribing networks—bypassing traditional retail pharmacy access bottlenecks; (5) Strategic In-Licensing of Chinese Incretin Assets: Western pharmaceutical giants are increasingly partnering with and acquiring regional rights to Chinese biotechs (e.g., Novo licensing Hengrui's HRS-1596 and United Laboratories' UBT251; Innovent advancing mazdutide) to expand pipeline diversity and lower development costs.

Search Keywords Brand Product

  • Zepbound
  • Mounjaro
  • Wegovy
  • Ozempic
  • Foundayo
  • Rybelsus
  • CagriSema
  • MariTide
  • retatrutide
  • orforglipron
  • petrelintide
  • mazdutide
  • pemvidutide
  • VK2735
  • aleniglipron
  • elecoglipron
  • berobenatide
  • zenagamtide
  • UBT251
  • BGM0504
  • obesity therapeutics
  • GLP-1 receptor agonist
  • next-generation weight loss drugs
  • triple hormone agonist
  • oral GLP-1
  • dual GIP GLP-1
  • amylin analog
  • cardiometabolic therapies

Search Keywords Policy Regulatory

  • Medicare GLP-1 coverage
  • Medicare Part D obesity coverage
  • GLP-1 Bridge program
  • FDA Biologics License Application
  • PBM formulary rebate
  • Medicaid obesity coverage
  • Most-Favored-Nations drug pricing

Search Keywords Event Phrases

  • ADA Scientific Sessions
  • ObesityWeek
  • EASD Annual Meeting
  • AHA Scientific Sessions
  • FDA advisory committee incretins
  • Medicare obesity coverage expansion

Google Trend Product Category Intent

• Wegovy pill • oral weight loss pill • Foundayo prescription • retatrutide clinical trial • monthly weight loss shot • oral GLP-1

Google Trend Consumer Intent

• how to get GLP-1 covered by insurance • GLP-1 side effects nausea • weight loss pill without injection • cheapest GLP-1 for weight loss • switch from Wegovy to Zepbound

Google Trend Macro Policy Terms

• Medicare covers weight loss drugs • Medicare GLP-1 Bridge • insurance coverage for obesity drugs • Medicaid Wegovy coverage

Economic Data Watch

1. FRED — Personal Consumption Expenditures

Matchedfred · access=api · map_only

Metric/field PCEPI

Cadence monthly

Why it matters Directly reflects overall spending by individuals on healthcare services and products in the U.S., indicating the size and growth of the addressable market for pharmaceutical companies.

Signal to watch Increasing PCEHC suggests a growing healthcare market, bullish for drug producers.

Confidence: high

2. FRED — Consumer Price Index

Matchedfred · access=api · map_only

Metric/field CPIMEDSL

Cadence monthly

Why it matters Tracks inflation specifically for medical care services in the U.S., which can influence drug pricing strategies, reimbursement discussions, and patient out-of-pocket costs.

Signal to watch Lower or stable CPIMEDSL could alleviate pricing pressures, while accelerating inflation may intensify them.

Confidence: high

3. FRED — Personal Income and Outlays

Matchedfred · access=api · map_only

Cadence monthly

Why it matters Represents the income available to households after taxes, directly impacting patient affordability and willingness to pay for new, often expensive, obesity treatments.

Signal to watch Rising disposable income indicates greater patient capacity for out-of-pocket expenses, supporting prescription growth.

Confidence: low

4. Trading Economics — GDP Growth Annual

Not in registryaccess=scrape

Metric/field China GDP Growth Annual

Cadence quarterly

Why it matters Economic growth in China, a significant market for several theme members (Innovent, Hengrui, Roche), influences healthcare spending, market access, and regulatory reforms.

Signal to watch Stronger GDP growth in China can support increased healthcare investment and drug adoption.

Confidence: high

5. Trading Economics — Retail Sales Annual

Not in registryaccess=scrape

Metric/field United Kingdom Retail Sales Annual

Cadence monthly

Why it matters Retail sales in the UK, a key international market for launches like Novo Nordisk's Wegovy pill, can serve as a proxy for consumer confidence and discretionary spending on health-related products.

Signal to watch Positive retail sales growth suggests robust consumer demand and potential for new drug uptake.

Confidence: high

Free Alt Data Watch

1. ClinicalTrials.gov — Clinical Trial Status Updates

Not in registry

Metric/field Status updates for 'obesity' AND 'GLP-1' trials

Cadence daily

Why it matters Provides real-time insights into the progress, enrollment, and completion of clinical trials for new obesity and GLP-1 related drugs, directly impacting pipeline valuation and future market entrants.

Signal to watch Increased trial completions, positive status changes, or new trial initiations are bullish signals for pipeline strength.

Confidence: high

2. CMS.gov — Medicare Part D Prescription Drug Event Data

Not in registry

Metric/field GLP-1 utilization under Medicare Part D

Cadence irregular

Why it matters Monitors the uptake and spending on GLP-1 drugs within the Medicare Part D program, particularly relevant for the Medicare GLP-1 Bridge program and its impact on patient access and company revenues.

Signal to watch Increasing utilization and spending on GLP-1s in Medicare Part D indicates expanded access and market penetration.

Confidence: medium

3. Google Trends — Web Search Interest

Not in registry

Metric/field Web Search Interest (relative volume) for 'Wegovy', 'Ozempic', 'Zepbound', 'Mounjaro', 'Foundayo', 'MariTide'

Cadence daily

Why it matters Reflects consumer awareness and interest in key GLP-1 drugs, serving as an early indicator of potential prescription demand and market sentiment.

Signal to watch Sustained or increasing search interest for these drugs suggests growing patient awareness and potential demand.

Confidence: high

4. FDA — Drug Approvals and Regulatory Actions

Not in registry

Metric/field New Drug Approvals for 'obesity' or 'diabetes' (specifically GLP-1s)

Cadence event_driven

Why it matters Tracks regulatory milestones, including new drug approvals or expanded indications, which are critical for market entry and revenue generation for pharmaceutical companies.

Signal to watch New approvals or positive regulatory actions for GLP-1s or related obesity treatments are bullish signals.

Confidence: high

5. LinkedIn Company Pages — Job Postings

Not in registry

Metric/field Job postings for 'GLP-1' or 'obesity' related roles at Eli Lilly, Novo Nordisk, Amgen, Pfizer, Roche

Cadence weekly

Why it matters Hiring trends in specific therapeutic areas like GLP-1 and obesity can indicate a company's investment, commercialization efforts, and confidence in future growth.

Signal to watch Increased hiring for commercial, R&D, or manufacturing roles related to GLP-1/obesity suggests expansion and confidence.

Confidence: medium

Paid Alt Data Watch

1. IQVIA — Xponent Data Feed

Matchediqvia_prescription_rx_data · access=file · map_only

Metric/field Weekly Total Prescriptions (TRx) and New Prescriptions (NBRx) for 'Wegovy', 'Ozempic', 'Zepbound', 'Mounjaro', 'Foundayo', 'MariTide' in the U.S.

Cadence weekly

Why it matters Provides direct, granular insight into market adoption, growth trajectory, and competitive dynamics of key GLP-1 drugs, crucial for assessing market share and revenue potential.

Signal to watch Consistent growth in TRx and NBRx, especially for newer drugs or those expanding indications, is a bullish signal.

Confidence: high

2. Komodo Health — Healthcare Map

Matched (medium)iqvia_patient_flows_longitudinal_healthcare · access=file · map_only

Metric/field De-identified patient journeys, treatment adherence, and comorbidity analysis for obesity and diabetes patients on GLP-1 therapies

Cadence monthly

Why it matters Offers deep insights into real-world patient behavior, adherence rates, switching patterns, and the impact of GLP-1s on associated comorbidities, informing market opportunity and drug differentiation.

Signal to watch Improved adherence, longer treatment duration, or positive impact on comorbidities for GLP-1 users are bullish indicators.

Confidence: high

3. Similarweb — Digital Research Intelligence

Matchedsimilarweb_website_traffic_engagement · access=file · map_only

Metric/field Website traffic, unique visitors, and engagement metrics for `lilly.com`, `novonordisk.com`, `amgen.com`, `pfizer.com`, `roche.com`

Cadence monthly

Why it matters Measures digital engagement and consumer interest in the pharmaceutical companies and their products, acting as a proxy for brand awareness and potential patient acquisition.

Signal to watch Increasing web traffic and engagement for company websites, particularly those promoting obesity treatments, suggests growing interest.

Confidence: high

4. GlobalData Healthcare — KOL Insights

Not in registry

Metric/field KOL survey results on physician perceptions, prescribing intent, and competitive landscape for next-generation obesity drugs

Cadence quarterly

Why it matters Provides expert opinion from Key Opinion Leaders (KOLs) on the efficacy, tolerability, and market potential of current and pipeline obesity treatments, offering forward-looking insights.

Signal to watch Positive sentiment from KOLs regarding new or differentiated GLP-1 therapies is a bullish signal for future adoption.

Confidence: high

5. Revelio Labs — Hiring Data

Matched (medium)revelio_labs_hiring_attrition · access=file · map_only

Metric/field Job postings and talent acquisition trends for 'GLP-1' and 'obesity' roles across the pharmaceutical industry

Cadence monthly

Why it matters Offers granular insights into talent investment and strategic focus within the GLP-1 and obesity market, indicating where companies are allocating resources for R&D, manufacturing, and commercialization.

Signal to watch Significant increases in hiring for GLP-1/obesity-related roles across multiple companies suggest robust industry growth and competition.

Confidence: high

Prediction Market Watch

1. When will CMS announce the addition of GLP-1 drugs for obesity to Part D? (Before Jan 20, 2029)

Kalshi · Confidence: high

Not in registryaccess=api

Market https://kalshi.com/markets/kxpartdglp1

Why it matters A CMS announcement adding GLP-1 drugs for obesity to Medicare Part D would significantly expand the addressable market for all theme constituents, including major players like Eli Lilly and Novo Nordisk, directly boosting prescription growth and revenue potential by increasing patient access and reimbursement.

Series key pm_cms_partd_glp1_announcement

2. Which companies will be acquired this year? (Before Jan 1, 2027)

Kalshi · Confidence: high

Not in registryaccess=api

Market https://kalshi.com/markets/kxacqannounceannual

Why it matters This contract includes Viking Therapeutics (VKTX), a key constituent in the theme developing next-generation dual GLP-1/GIP agonists. An acquisition of Viking would signal increased consolidation and strategic interest in the obesity drug market, potentially impacting the competitive landscape and valuation of other emerging players in the theme.

Series key pm_vktx_acquisition

Theme Plain English
This theme captures pharmaceutical and biotechnology companies developing and commercializing medicines for obesity and related metabolic diseases. While first-generation treatments established the market through weekly GLP-1 peptide injections, the theme focuses on the transition toward next-generation therapies. These include convenient once-daily oral pills, longer-acting monthly injections, multi-receptor agonists targeting GIP or glucagon, and amylin combinations designed to deliver superior weight reduction, improved muscle preservation, fewer gastrointestinal side effects, and expanded access.
Upcoming Catalysts12 rows
Catalyst IDEstimated TimingEstimated Date StartEstimated Date EndCatalystWhy It MattersTicker Or Theme SpecificTranscript DateSource TypeCatalyst Source
LLY_10dadbebby year end2026-10-012026-12-31European regulatory approval for Foundayo (chronic weight management and type 2 diabetes) following a positive CHMP opinion.This approval is crucial for the anticipated global rollout of Foundayo in major markets in 2027, significantly expanding its international revenue potential.Ticker2026-10-29earnings_transcriptLLY (ticker)
LLY_48d9403dlater this year2026-10-012026-12-31Readout of Foundayo Phase 3 trial in obstructive sleep apnea.Positive results from this trial could lead to a new, high-value indication for Foundayo, further expanding its utility and market potential beyond its current metabolic indications.Ticker2026-08-05earnings_transcriptLLY (ticker)
LLY_696cb569later this year2026-10-012026-12-31U.S. regulatory action (approval/decision) for Foundayo in type 2 diabetes.This regulatory decision would significantly expand Foundayo's addressable market in the U.S. to include type 2 diabetes, a large and established indication, driving substantial revenue growth.Ticker2026-08-05earnings_transcriptLLY (ticker)
LLY_cf82d1b5a few markets late in 20262026-10-012026-12-31Launch of Orforglipron in a few international markets (e.g., UAE).This marks the beginning of the international rollout for oral Orforglipron, contributing to global revenue growth and market penetration.Ticker2026-02-04earnings_transcriptLLY (ticker)
AMGN_fe4d51bfWe will update you on those discussions as necessary.2026-04-242026-12-31Resolution of ongoing discussions with the FDA regarding TABNIO's (avacopan) following a voluntary withdrawal request related to primary endpoint result readjudication.The outcome will determine the future commercial viability of TABNIO's, impacting Amgen's rare disease portfolio and potentially leading to a re-evaluation of the product's sales trajectory.Ticker2026-02-03earnings_transcriptAMGN (ticker)
NVO_71e5b33dat the end of 20262026-10-012026-12-31FDA regulatory decision for CagriSema in the U.S. for obesity.Approval would introduce a new, potentially highly effective obesity treatment, strengthening Novo Nordisk's pipeline and competitive position.Ticker2026-05-06earnings_transcriptNVO (ticker)
PFE_fe771000fourth quarter2026-10-012026-12-31First readout of the MEVPRO-1 Phase III study for mevrometostat in post-abiraterone metastatic hormone-resistant prostate cancer.This pivotal study readout could establish mevrometostat as a breakthrough therapy, delaying resistance to XTANDI and representing a 100% global commercial opportunity for Pfizer.Ticker2026-08-04earnings_transcriptPFE (ticker)
PFE_0a01f9d3later this year at a conference2026-09-012026-12-31Presentation of the full data set from the TRANQUILLO 1 and 2 studies for Litfulo in nonsegmental vitiligo.The full data presentation will provide comprehensive insights into Litfulo's clinically meaningful and statistical efficacy, reinforcing its potential in the vitiligo market.Ticker2026-08-04earnings_transcriptPFE (ticker)
PFE_a3b83d3fthis year2026-09-012026-12-31Start of a pivotal trial investigating NURTEC's use as a treatment for chronic migraine.This pivotal trial initiation aims to expand NURTEC's label, further strengthening Pfizer's leadership in providing treatment options for migraine patients.Ticker2026-08-04earnings_transcriptPFE (ticker)
PFE_a1fcc382later this year2026-09-012026-12-31Release of the clinical trial design for the adjuvant study of atirmociclib in ER-positive breast cancer.This milestone is crucial for advancing atirmociclib, which is believed to be highly differentiated in the early adjuvant setting due to its tolerability profile, representing a significant opportunity.Ticker2026-08-04earnings_transcriptPFE (ticker)
LLY_a24ab55bDecember 7th2026-12-072026-12-07Lilly Innovation Day.This event is expected to provide more detailed insights into Lilly's pipeline, potentially revealing new material information about future growth drivers and strategic priorities.Ticker2026-10-29earnings_transcriptLLY (ticker)
LLY_a075099bQ1 20272027-01-012027-03-31U.S. regulatory submission (BLA pathway) for retatrutide.This submission is a critical step towards bringing the highly efficacious triple agonist, retatrutide, to market, potentially solidifying Lilly's leadership in cardiometabolic health with a drug demonstrating unprecedented weight loss.Ticker2026-10-29earnings_transcriptLLY (ticker)

News

10 stories tagged to this theme — Narrative Radar and editorial picks.

October 2026

Loading correlation…

Constituents

  • LLYT13.5%
    — Eli Lilly and Company
  • — Innovent Biologics, Inc.
  • — The United Laboratories International Holdings Limited
  • — Amgen Inc.
  • NVOT3
    — Novo Nordisk A/S
  • PFET3
    — Pfizer Inc.
  • — Roche Holding AG
  • 600276.SHGT3
    · no notes yet
  • 688166.SHGT3
    · no notes yet
  • ALTT3
    · no notes yet
  • AZNT3
    · no notes yet
  • GPCRT3
    · no notes yet
  • KLRAT3
    · no notes yet
  • VKTXT3
    · no notes yet
  • ZEAL.COT3
    · no notes yet